Literature DB >> 22372727

Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer.

Lesley J Scott1, Lily P H Yang2, Katherine A Lyseng-Williamson2.   

Abstract

Oral abiraterone acetate (Zytiga®), a selective cytochrome P450 17A1 enzyme inhibitor, is used in combination with prednisone or prednisolone to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. In a clinical trial in patients with CRPC, abiraterone acetate plus prednisone significantly prolonged overall survival, the time to prostate-specific antigen progression and progression-free survival compared with placebo plus prednisone.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22372727     DOI： 10.2165/11209160-000000000-00000

Source DB:  PubMed          Journal:  Drugs Aging        ISSN： 1170-229X            Impact factor:   3.923


  6 in total

1.  Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  A Horwich; C Parker; C Bangma; V Kataja
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  Abiraterone acetate: in metastatic castration-resistant prostate cancer.

Authors:  Lily P H Yang
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

3.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

4.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Authors:  Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Hans-Peter Schmid; Theo Van der Kwast; Thomas Wiegel; Filiberto Zattoni; Axel Heidenreich
Journal:  Eur Urol       Date:  2011-01-25       Impact factor: 20.096

5.  Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

Authors:  Eric J Small; Susan Halabi; Nancy A Dawson; Walter M Stadler; Brian I Rini; Joel Picus; Preston Gable; Frank M Torti; Ellen Kaplan; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

Review 6.  Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.

Authors:  A Oliver Sartor
Journal:  J Hematol Oncol       Date:  2011-04-23       Impact factor: 17.388
  6 in total
  1 in total

Review 1.  Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy.

Authors:  Inna Armandari; Agus Rizal Hamid; Gerald Verhaegh; Jack Schalken
Journal:  Prostate Int       Date:  2014-08-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.